NCT00000747View on ClinicalTrials.gov

An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

Not specified

Primary Completion Date

December 31, 1994

Conditions
HIV Infections
Interventions
DRUG

Nevirapine

Trial Locations (1)

92103

UCSD, San Diego

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH